Cytokinetics, Inc.  

(Public, NASDAQ:CYTK)   Watch this stock  
Find more results for CYTK
7.02
+0.17 (2.48%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.66 - 7.03
52 week 5.50 - 13.18
Open 6.92
Vol / Avg. 359,129.00/442,302.00
Mkt cap 266.86M
P/E     -
Div/yield     -
EPS -0.50
Shares 38.85M
Beta 1.24
Inst. own 58%
Feb 23, 2016
Cytokinetics Inc at SunTrust Robinson Humphrey Orphan Drug Day Add to calendar
Feb 16, 2016
Q4 2015 Cytokinetics Inc Earnings Call - 4:30PM EST - Add to calendar
Feb 16, 2016
Q4 2015 Cytokinetics Inc Earnings Release - 4:00PM EST - Add to calendar
Feb 8, 2016
Cytokinetics Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference
Dec 1, 2015
Cytokinetics Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -111.38% -31.20%
Operating margin -111.87% -31.43%
EBITD margin - -30.39%
Return on average assets -33.03% -13.55%
Return on average equity -49.93% -19.99%
Employees 92 -
CDP Score - -

Address

280 E Grand Ave
SOUTH SAN FRANCISCO, CA 94080-4808
United States - Map
+1-650-6243000 (Phone)
+1-650-6243010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cytokinetics, Incorporated is a clinical stage biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Company's drug candidates that are in clinical development are its skeletal muscle activators tirasemtiv and CK-2127107 and its cardiac muscle activator omecamtiv mecarbil. Tirasemtiv and CK-2127107 are structurally distinct and selective small molecules that activate the fast skeletal muscle troponin complex in the sarcomere by increasing its sensitivity to calcium, leading to an increase in skeletal muscle contractility. COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure) is a Phase II clinical trial designed to assess the pharmacokinetics and tolerability of omecamtiv mecarbil dosed orally in patients with heart failure and left ventricular systolic dysfunction.

Officers and directors

Leonard Patrick Gage Ph.D. Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Robert I. Blum President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Sharon A. Barbari Chief Financial Officer, Executive Vice President - Finance
Age: 61
Bio & Compensation  - Reuters
Fady I. Malik M.D. Ph.D. Executive Vice President - Research and Development
Age: 50
Bio & Compensation  - Reuters
David W. Cragg Senior Vice President - Human Resources
Age: 59
Bio & Compensation  - Reuters
Bonnie A. Charpentier Ph.D. Senior Vice President - Regulatory Affairs and Compliance
Age: 61
Bio & Compensation  - Reuters
Bradley Paul Morgan Senior Vice President - Drug Discovery and Early Development
Age: 55
Bio & Compensation  - Reuters
Andrew A. Wolff M.D. Senior Vice President - Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Santo Joseph Costa J.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
John T. Henderson M.D. Independent Director
Age: 71
Bio & Compensation  - Reuters